Ahn-Gook Pharmaceutical (A001540) 주식 개요안국약품(주)는 의약품을 제조 및 판매하는 회사입니다. 자세히 보기A001540 펀더멘털 분석스노우플레이크 점수가치 평가3/6미래 성장0/6과거 실적3/6재무 건전성5/6배당2/6강점공정 가치 추정치보다 낮은 95.9% 에서 거래지난 5년 동안 수입이 매년 31.6% 증가했습니다.위험 분석우리의 위험 점검에서 A001540에 대한 위험이 감지되지 않았습니다.모든 위험 점검 보기A001540 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW478,504 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA478,504 investors already sharing narrativesYour Fair Value₩Current Price₩12.56k32.9% 저평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-3b693b2016201920222025202620282031Revenue ₩692.7bEarnings ₩34.1bAdvancedSet Fair ValueView all narrativesAhn-Gook Pharmaceutical Co., Ltd. 경쟁사Dongwha Pharm.Co.LtdSymbol: KOSE:A000020Market cap: ₩138.9bIlyang PharmaceuticalLtdSymbol: KOSE:A007570Market cap: ₩151.8bKyung Dong PharmaceuticalSymbol: KOSDAQ:A011040Market cap: ₩134.0bJW LifescienceSymbol: KOSE:A234080Market cap: ₩176.5b가격 이력 및 성과Ahn-Gook Pharmaceutical 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가₩12,910.0052주 최고가₩12,930.0052주 최저가₩7,280.00베타0.761개월 변동15.27%3개월 변동65.94%1년 변동66.15%3년 변동54.80%5년 변동3.69%IPO 이후 변동20.19%최근 뉴스 및 업데이트Valuation Update With 7 Day Price Move • Jul 30Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩9,960, the stock trades at a trailing P/E ratio of 7x. Average trailing P/E is 9x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 44% over the past three years.Valuation Update With 7 Day Price Move • Jul 15Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩12,130, the stock trades at a trailing P/E ratio of 8.5x. Average trailing P/E is 10x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 77% over the past three years.분석 기사 • Jul 10Is Now The Time To Put Ahn-Gook Pharmaceutical (KOSDAQ:001540) On Your Watchlist?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Valuation Update With 7 Day Price Move • May 14Investor sentiment improves as stock rises 28%After last week's 28% share price gain to ₩10,200, the stock trades at a trailing P/E ratio of 15.5x. Average trailing P/E is 14x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 44% over the past three years.분석 기사 • Mar 27Some May Be Optimistic About Ahn-Gook Pharmaceutical's (KOSDAQ:001540) EarningsThe market for Ahn-Gook Pharmaceutical Co., Ltd.'s ( KOSDAQ:001540 ) shares didn't move much after it posted weak...Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩7,280, the stock trades at a trailing P/E ratio of 8.4x. Average trailing P/E is 17x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 4.0% over the past three years.더 많은 업데이트 보기Recent updatesValuation Update With 7 Day Price Move • Jul 30Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩9,960, the stock trades at a trailing P/E ratio of 7x. Average trailing P/E is 9x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 44% over the past three years.Valuation Update With 7 Day Price Move • Jul 15Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩12,130, the stock trades at a trailing P/E ratio of 8.5x. Average trailing P/E is 10x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 77% over the past three years.분석 기사 • Jul 10Is Now The Time To Put Ahn-Gook Pharmaceutical (KOSDAQ:001540) On Your Watchlist?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Valuation Update With 7 Day Price Move • May 14Investor sentiment improves as stock rises 28%After last week's 28% share price gain to ₩10,200, the stock trades at a trailing P/E ratio of 15.5x. Average trailing P/E is 14x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 44% over the past three years.분석 기사 • Mar 27Some May Be Optimistic About Ahn-Gook Pharmaceutical's (KOSDAQ:001540) EarningsThe market for Ahn-Gook Pharmaceutical Co., Ltd.'s ( KOSDAQ:001540 ) shares didn't move much after it posted weak...Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩7,280, the stock trades at a trailing P/E ratio of 8.4x. Average trailing P/E is 17x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 4.0% over the past three years.공고 • Feb 27Ahn-Gook Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2026Ahn-Gook Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 12, gwacheon-daero 7-gil, gyeonggi-do, gwacheon South KoreaUpcoming Dividend • Dec 22Upcoming dividend of ₩440 per shareEligible shareholders must have bought the stock before 29 December 2025. Payment date: 20 April 2026. Payout ratio is a comfortable 51% and this is well supported by cash flows. Trailing yield: 4.9%. Within top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (0.8%).분석 기사 • Dec 02Earnings Working Against Ahn-Gook Pharmaceutical Co., Ltd.'s (KOSDAQ:001540) Share PriceWhen close to half the companies in Korea have price-to-earnings ratios (or "P/E's") above 14x, you may consider...Declared Dividend • Nov 08Dividend of ₩440 announcedDividend of ₩440 is the same as last year. Ex-date: 29th December 2025 Payment date: 20th April 2026 Dividend yield will be 5.6%, which is higher than the industry average of 1.1%. Sustainability & Growth Dividend is covered by both earnings (82% earnings payout ratio) and cash flows (17% cash payout ratio). The dividend has increased by an average of 12% per year over the past 6 years and payments have been stable during that time. Earnings per share has grown by 96% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.공고 • Nov 07Ahn-Gook Pharmaceutical Co., Ltd. announces Annual dividend, payable on April 20, 2026Ahn-Gook Pharmaceutical Co., Ltd. announced Annual dividend of KRW 440.0000 per share payable on April 20, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.New Risk • Aug 24New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 2.1% Last year net profit margin: 6.1% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (2.1% net profit margin). Market cap is less than US$100m (₩86.7b market cap, or US$62.7m).분석 기사 • Mar 28Shareholders Shouldn’t Be Too Comfortable With Ahn-Gook Pharmaceutical's (KOSDAQ:001540) Strong EarningsEven though Ahn-Gook Pharmaceutical Co., Ltd. ( KOSDAQ:001540 ) posted strong earnings recently, the stock hasn't...Buy Or Sell Opportunity • Mar 18Now 20% overvaluedOver the last 90 days, the stock has fallen 2.6% to ₩6,630. The fair value is estimated to be ₩5,511, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 37%.Buy Or Sell Opportunity • Feb 25Now 21% overvaluedOver the last 90 days, the stock has fallen 3.9% to ₩6,650. The fair value is estimated to be ₩5,511, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 37%.공고 • Feb 20Ahn-Gook Pharmaceutical Co., Ltd., Annual General Meeting, Mar 28, 2025Ahn-Gook Pharmaceutical Co., Ltd., Annual General Meeting, Mar 28, 2025, at 09:00 Tokyo Standard Time. Location: auditorium, 12, gwacheon-daero 7-gil, gyeonggi-do, gwacheon South KoreaUpcoming Dividend • Dec 20Upcoming dividend of ₩220 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 18 April 2025. Payout ratio is a comfortable 18% but the company is not cash flow positive. Trailing yield: 3.3%. Lower than top quartile of South Korean dividend payers (3.9%). Higher than average of industry peers (1.1%).Declared Dividend • Nov 27Dividend of ₩220 announcedShareholders will receive a dividend of ₩220. Ex-date: 27th December 2024 Payment date: 18th April 2025 Dividend yield will be 3.2%, which is higher than the industry average of 1.1%. Sustainability & Growth Dividend is covered by earnings (18% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has not increased over the past 5 years but payments have been stable during that time. Earnings per share has grown by 14% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.분석 기사 • Aug 26Statutory Earnings May Not Be The Best Way To Understand Ahn-Gook Pharmaceutical's (KOSDAQ:001540) True PositionWe didn't see Ahn-Gook Pharmaceutical Co., Ltd.'s ( KOSDAQ:001540 ) stock surge when it reported robust earnings...분석 기사 • Aug 13Pinning Down Ahn-Gook Pharmaceutical Co., Ltd.'s (KOSDAQ:001540) P/E Is Difficult Right NowWith a price-to-earnings (or "P/E") ratio of 13.7x Ahn-Gook Pharmaceutical Co., Ltd. ( KOSDAQ:001540 ) may be sending...New Risk • Jun 01New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 53% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (53% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (2.6% net profit margin). Market cap is less than US$100m (₩85.5b market cap, or US$61.9m).New Risk • May 13New major risk - Dividend sustainabilityThe dividend is not well covered by earnings and cash flows. Payout ratio: 194% The company is paying a dividend despite having no free cash flows. Dividend yield: 2.9% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 194% Paying a dividend despite having no free cash flows. Earnings have declined by 8.1% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.6% net profit margin). Market cap is less than US$100m (₩86.8b market cap, or US$63.5m).New Risk • Mar 26New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 28% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 8.1% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.6% net profit margin). Market cap is less than US$100m (₩93.7b market cap, or US$70.0m).Reported Earnings • Mar 26Full year 2023 earnings released: EPS: ₩114 (vs ₩604 in FY 2022)Full year 2023 results: EPS: ₩114 (down from ₩604 in FY 2022). Revenue: ₩233.7b (up 14% from FY 2022). Net income: ₩1.29b (down 81% from FY 2022). Profit margin: 0.6% (down from 3.3% in FY 2022). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.Upcoming Dividend • Dec 20Upcoming dividend of ₩220 per share at 2.7% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 18 April 2024. Payout ratio is a comfortable 55% but the company is not cash flow positive. Trailing yield: 2.7%. Lower than top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (1.1%).New Risk • Nov 22New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 2.0% Last year net profit margin: 4.8% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 6.4% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (2.0% net profit margin). Market cap is less than US$100m (₩89.0b market cap, or US$68.7m).Upcoming Dividend • Dec 21Upcoming dividend of ₩220 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 18 April 2023. Payout ratio is a comfortable 26% but the company is paying out more than the cash it is generating. Trailing yield: 2.2%. Lower than top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (1.0%).Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Valuation Update With 7 Day Price Move • Aug 04Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₩10,100, the stock trades at a trailing P/E ratio of 28.3x. Average trailing P/E is 23x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 19% over the past three years.Valuation Update With 7 Day Price Move • Jun 23Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩7,310, the stock trades at a trailing P/E ratio of 20.5x. Average trailing P/E is 20x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 31% over the past three years.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Upcoming Dividend • Dec 22Upcoming dividend of ₩220 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 11 April 2022. The company is paying out more than 100% of its profits and is cash flow negative. Trailing yield: 2.1%. Lower than top quartile of South Korean dividend payers (2.4%). Higher than average of industry peers (0.8%).분석 기사 • Apr 02Are Dividend Investors Making A Mistake With Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540)?Dividend paying stocks like Ahn-Gook Pharmaceutical Co., Ltd. ( KOSDAQ:001540 ) tend to be popular with investors, and...Is New 90 Day High Low • Mar 09New 90-day low: ₩12,550The company is down 2.0% from its price of ₩12,800 on 09 December 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 22% over the same period.분석 기사 • Mar 07Ahn-Gook Pharmaceutical (KOSDAQ:001540) Shareholders Booked A 29% Gain In The Last YearWe believe investing is smart because history shows that stock markets go higher in the long term. But if you choose...분석 기사 • Feb 14Is Ahn-Gook Pharmaceutical (KOSDAQ:001540) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...분석 기사 • Jan 19Do Insiders Own Lots Of Shares In Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540)?A look at the shareholders of Ahn-Gook Pharmaceutical Co., Ltd. ( KOSDAQ:001540 ) can tell us which group is most...Is New 90 Day High Low • Jan 15New 90-day high: ₩15,250The company is up 15% from its price of ₩13,250 on 16 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 20% over the same period.분석 기사 • Dec 24Dividend Investors: Don't Be Too Quick To Buy Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540) For Its Upcoming DividendSome investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...분석 기사 • Dec 10A Look At The Fair Value Of Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540)Does the December share price for Ahn-Gook Pharmaceutical Co., Ltd. ( KOSDAQ:001540 ) reflect what it's really worth...분석 기사 • Nov 18Key Things To Consider Before Buying Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540) For Its DividendCould Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540) be an attractive dividend share to own for the long haul...Is New 90 Day High Low • Oct 15New 90-day low: ₩13,250The company is down 2.0% from its price of ₩13,500 on 17 July 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 12% over the same period.주주 수익률A001540KR PharmaceuticalsKR 시장7D26.4%10.3%-4.2%1Y66.2%-8.0%84.8%전체 주주 수익률 보기수익률 대 산업: A001540은 지난 1년 동안 -8%의 수익을 기록한 KR Pharmaceuticals 산업보다 더 좋은 성과를 냈습니다.수익률 대 시장: A001540은 지난 1년 동안 84.8%를 기록한 KR 시장보다 저조한 성과를 냈습니다.주가 변동성Is A001540's price volatile compared to industry and market?A001540 volatilityA001540 Average Weekly Movement11.9%Pharmaceuticals Industry Average Movement7.2%Market Average Movement9.9%10% most volatile stocks in KR Market17.8%10% least volatile stocks in KR Market5.2%안정적인 주가: A001540는 지난 3개월 동안 KR 시장에 비해 주가 변동성이 크지 않았습니다.시간에 따른 변동성: A001540의 주간 변동성(12%)은 지난 1년 동안 안정적이었습니다.회사 소개설립직원 수CEO웹사이트1959391June-Sun Auhwww.ahn-gook.com안국약품은 의약품을 제조 및 판매합니다. 이 회사의 의약품에는 시나투라 및 레보 텐션이 포함됩니다. 이 회사는 1959년에 설립되었으며 본사는 대한민국 서울에 있습니다.더 보기Ahn-Gook Pharmaceutical Co., Ltd. 기초 지표 요약Ahn-Gook Pharmaceutical의 순이익과 매출은 시가총액과 어떻게 비교됩니까?A001540 기초 통계시가총액₩146.73b순이익 (TTM)₩16.27b매출 (TTM)₩330.05b9.0x주가수익비율(P/E)0.4x주가매출비율(P/S)A001540는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표A001540 손익계산서 (TTM)매출₩330.05b매출원가₩111.92b총이익₩218.13b기타 비용₩201.86b순이익₩16.27b최근 보고된 실적Mar 31, 2026다음 실적 발표일해당 없음주당순이익(EPS)1.43k총이익률66.09%순이익률4.93%부채/자본 비율45.4%A001540의 장기 실적은 어땠습니까?과거 실적 및 비교 보기배당3.4%현재 배당 수익률n/a배당 성향View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/09 10:28종가2026/08/07 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Ahn-Gook Pharmaceutical Co., Ltd.는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Min-young LeeKorea Investment & Securities Co., Ltd.
Valuation Update With 7 Day Price Move • Jul 30Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩9,960, the stock trades at a trailing P/E ratio of 7x. Average trailing P/E is 9x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 44% over the past three years.
Valuation Update With 7 Day Price Move • Jul 15Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩12,130, the stock trades at a trailing P/E ratio of 8.5x. Average trailing P/E is 10x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 77% over the past three years.
분석 기사 • Jul 10Is Now The Time To Put Ahn-Gook Pharmaceutical (KOSDAQ:001540) On Your Watchlist?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Valuation Update With 7 Day Price Move • May 14Investor sentiment improves as stock rises 28%After last week's 28% share price gain to ₩10,200, the stock trades at a trailing P/E ratio of 15.5x. Average trailing P/E is 14x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 44% over the past three years.
분석 기사 • Mar 27Some May Be Optimistic About Ahn-Gook Pharmaceutical's (KOSDAQ:001540) EarningsThe market for Ahn-Gook Pharmaceutical Co., Ltd.'s ( KOSDAQ:001540 ) shares didn't move much after it posted weak...
Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩7,280, the stock trades at a trailing P/E ratio of 8.4x. Average trailing P/E is 17x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 4.0% over the past three years.
Valuation Update With 7 Day Price Move • Jul 30Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩9,960, the stock trades at a trailing P/E ratio of 7x. Average trailing P/E is 9x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 44% over the past three years.
Valuation Update With 7 Day Price Move • Jul 15Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩12,130, the stock trades at a trailing P/E ratio of 8.5x. Average trailing P/E is 10x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 77% over the past three years.
분석 기사 • Jul 10Is Now The Time To Put Ahn-Gook Pharmaceutical (KOSDAQ:001540) On Your Watchlist?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Valuation Update With 7 Day Price Move • May 14Investor sentiment improves as stock rises 28%After last week's 28% share price gain to ₩10,200, the stock trades at a trailing P/E ratio of 15.5x. Average trailing P/E is 14x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 44% over the past three years.
분석 기사 • Mar 27Some May Be Optimistic About Ahn-Gook Pharmaceutical's (KOSDAQ:001540) EarningsThe market for Ahn-Gook Pharmaceutical Co., Ltd.'s ( KOSDAQ:001540 ) shares didn't move much after it posted weak...
Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩7,280, the stock trades at a trailing P/E ratio of 8.4x. Average trailing P/E is 17x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 4.0% over the past three years.
공고 • Feb 27Ahn-Gook Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2026Ahn-Gook Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 12, gwacheon-daero 7-gil, gyeonggi-do, gwacheon South Korea
Upcoming Dividend • Dec 22Upcoming dividend of ₩440 per shareEligible shareholders must have bought the stock before 29 December 2025. Payment date: 20 April 2026. Payout ratio is a comfortable 51% and this is well supported by cash flows. Trailing yield: 4.9%. Within top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (0.8%).
분석 기사 • Dec 02Earnings Working Against Ahn-Gook Pharmaceutical Co., Ltd.'s (KOSDAQ:001540) Share PriceWhen close to half the companies in Korea have price-to-earnings ratios (or "P/E's") above 14x, you may consider...
Declared Dividend • Nov 08Dividend of ₩440 announcedDividend of ₩440 is the same as last year. Ex-date: 29th December 2025 Payment date: 20th April 2026 Dividend yield will be 5.6%, which is higher than the industry average of 1.1%. Sustainability & Growth Dividend is covered by both earnings (82% earnings payout ratio) and cash flows (17% cash payout ratio). The dividend has increased by an average of 12% per year over the past 6 years and payments have been stable during that time. Earnings per share has grown by 96% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
공고 • Nov 07Ahn-Gook Pharmaceutical Co., Ltd. announces Annual dividend, payable on April 20, 2026Ahn-Gook Pharmaceutical Co., Ltd. announced Annual dividend of KRW 440.0000 per share payable on April 20, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.
New Risk • Aug 24New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 2.1% Last year net profit margin: 6.1% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (2.1% net profit margin). Market cap is less than US$100m (₩86.7b market cap, or US$62.7m).
분석 기사 • Mar 28Shareholders Shouldn’t Be Too Comfortable With Ahn-Gook Pharmaceutical's (KOSDAQ:001540) Strong EarningsEven though Ahn-Gook Pharmaceutical Co., Ltd. ( KOSDAQ:001540 ) posted strong earnings recently, the stock hasn't...
Buy Or Sell Opportunity • Mar 18Now 20% overvaluedOver the last 90 days, the stock has fallen 2.6% to ₩6,630. The fair value is estimated to be ₩5,511, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 37%.
Buy Or Sell Opportunity • Feb 25Now 21% overvaluedOver the last 90 days, the stock has fallen 3.9% to ₩6,650. The fair value is estimated to be ₩5,511, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 37%.
공고 • Feb 20Ahn-Gook Pharmaceutical Co., Ltd., Annual General Meeting, Mar 28, 2025Ahn-Gook Pharmaceutical Co., Ltd., Annual General Meeting, Mar 28, 2025, at 09:00 Tokyo Standard Time. Location: auditorium, 12, gwacheon-daero 7-gil, gyeonggi-do, gwacheon South Korea
Upcoming Dividend • Dec 20Upcoming dividend of ₩220 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 18 April 2025. Payout ratio is a comfortable 18% but the company is not cash flow positive. Trailing yield: 3.3%. Lower than top quartile of South Korean dividend payers (3.9%). Higher than average of industry peers (1.1%).
Declared Dividend • Nov 27Dividend of ₩220 announcedShareholders will receive a dividend of ₩220. Ex-date: 27th December 2024 Payment date: 18th April 2025 Dividend yield will be 3.2%, which is higher than the industry average of 1.1%. Sustainability & Growth Dividend is covered by earnings (18% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has not increased over the past 5 years but payments have been stable during that time. Earnings per share has grown by 14% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
분석 기사 • Aug 26Statutory Earnings May Not Be The Best Way To Understand Ahn-Gook Pharmaceutical's (KOSDAQ:001540) True PositionWe didn't see Ahn-Gook Pharmaceutical Co., Ltd.'s ( KOSDAQ:001540 ) stock surge when it reported robust earnings...
분석 기사 • Aug 13Pinning Down Ahn-Gook Pharmaceutical Co., Ltd.'s (KOSDAQ:001540) P/E Is Difficult Right NowWith a price-to-earnings (or "P/E") ratio of 13.7x Ahn-Gook Pharmaceutical Co., Ltd. ( KOSDAQ:001540 ) may be sending...
New Risk • Jun 01New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 53% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (53% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (2.6% net profit margin). Market cap is less than US$100m (₩85.5b market cap, or US$61.9m).
New Risk • May 13New major risk - Dividend sustainabilityThe dividend is not well covered by earnings and cash flows. Payout ratio: 194% The company is paying a dividend despite having no free cash flows. Dividend yield: 2.9% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 194% Paying a dividend despite having no free cash flows. Earnings have declined by 8.1% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.6% net profit margin). Market cap is less than US$100m (₩86.8b market cap, or US$63.5m).
New Risk • Mar 26New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 28% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 8.1% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.6% net profit margin). Market cap is less than US$100m (₩93.7b market cap, or US$70.0m).
Reported Earnings • Mar 26Full year 2023 earnings released: EPS: ₩114 (vs ₩604 in FY 2022)Full year 2023 results: EPS: ₩114 (down from ₩604 in FY 2022). Revenue: ₩233.7b (up 14% from FY 2022). Net income: ₩1.29b (down 81% from FY 2022). Profit margin: 0.6% (down from 3.3% in FY 2022). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
Upcoming Dividend • Dec 20Upcoming dividend of ₩220 per share at 2.7% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 18 April 2024. Payout ratio is a comfortable 55% but the company is not cash flow positive. Trailing yield: 2.7%. Lower than top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (1.1%).
New Risk • Nov 22New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 2.0% Last year net profit margin: 4.8% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 6.4% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (2.0% net profit margin). Market cap is less than US$100m (₩89.0b market cap, or US$68.7m).
Upcoming Dividend • Dec 21Upcoming dividend of ₩220 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 18 April 2023. Payout ratio is a comfortable 26% but the company is paying out more than the cash it is generating. Trailing yield: 2.2%. Lower than top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (1.0%).
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Aug 04Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₩10,100, the stock trades at a trailing P/E ratio of 28.3x. Average trailing P/E is 23x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 19% over the past three years.
Valuation Update With 7 Day Price Move • Jun 23Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩7,310, the stock trades at a trailing P/E ratio of 20.5x. Average trailing P/E is 20x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 31% over the past three years.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Upcoming Dividend • Dec 22Upcoming dividend of ₩220 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 11 April 2022. The company is paying out more than 100% of its profits and is cash flow negative. Trailing yield: 2.1%. Lower than top quartile of South Korean dividend payers (2.4%). Higher than average of industry peers (0.8%).
분석 기사 • Apr 02Are Dividend Investors Making A Mistake With Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540)?Dividend paying stocks like Ahn-Gook Pharmaceutical Co., Ltd. ( KOSDAQ:001540 ) tend to be popular with investors, and...
Is New 90 Day High Low • Mar 09New 90-day low: ₩12,550The company is down 2.0% from its price of ₩12,800 on 09 December 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 22% over the same period.
분석 기사 • Mar 07Ahn-Gook Pharmaceutical (KOSDAQ:001540) Shareholders Booked A 29% Gain In The Last YearWe believe investing is smart because history shows that stock markets go higher in the long term. But if you choose...
분석 기사 • Feb 14Is Ahn-Gook Pharmaceutical (KOSDAQ:001540) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
분석 기사 • Jan 19Do Insiders Own Lots Of Shares In Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540)?A look at the shareholders of Ahn-Gook Pharmaceutical Co., Ltd. ( KOSDAQ:001540 ) can tell us which group is most...
Is New 90 Day High Low • Jan 15New 90-day high: ₩15,250The company is up 15% from its price of ₩13,250 on 16 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 20% over the same period.
분석 기사 • Dec 24Dividend Investors: Don't Be Too Quick To Buy Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540) For Its Upcoming DividendSome investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...
분석 기사 • Dec 10A Look At The Fair Value Of Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540)Does the December share price for Ahn-Gook Pharmaceutical Co., Ltd. ( KOSDAQ:001540 ) reflect what it's really worth...
분석 기사 • Nov 18Key Things To Consider Before Buying Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540) For Its DividendCould Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540) be an attractive dividend share to own for the long haul...
Is New 90 Day High Low • Oct 15New 90-day low: ₩13,250The company is down 2.0% from its price of ₩13,500 on 17 July 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 12% over the same period.
